Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.50 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.50 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 5/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7205663 | 1.00 | LMNA (0.51) | LMNAMAPTHTR2ADRD2HRH1 | |
| Fumaric Acid SCHEMBL7205504 | 0.88 | DRD2 (0.55) | HTR2ADRD2HTR7HTR1ASLC6A4 | |
| Fumaric Acid SCHEMBL7205491 | 0.88 | DRD2 (0.55) | HTR2ADRD2HTR7HTR1ASLC6A4 | |
| Fumaric Acid SCHEMBL7212904 | 0.87 | HTR1A (0.63) | LMNAMAPTDRD2HTR1ADRD3 | |
| Fumaric Acid SCHEMBL7212900 | 0.87 | HTR1A (0.63) | LMNAMAPTDRD2HTR1ADRD3 | |
| SCHEMBL8691834 | 0.82 | HRH3 (0.58) | LMNAPOLBKDM4E | |
| SCHEMBL7207251 | 0.81 | KDM4E (0.51) | LMNAHTR2ADRD2HRH1HTR7 | |
| SCHEMBL8694610 | 0.80 | KDM4E (0.67) | LMNAMAPTTP53POLBKDM4E | |
| SCHEMBL8691850 | 0.80 | HRH3 (0.65) | HRH1 | |
| Bromide SCHEMBL7207307 | 0.80 | DRD2 (0.50) | LMNAHTR2ADRD2HRH1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | claimed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | claimed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6313141-B1 | FOR THERAPY OF SCHIZOPHRENIA, PSYCHOTIC DEPRESSION, MANIA, PARKINSON'S DISEASE AND TARDIVE DISKINESIA | NEUROGEN CORPORATION | 2001-11-06 | — | — | US | disclosed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5972945-A | FOR TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | SLC6A3, DRD4, ADRA2C | HTR2A 80/4885DRD2 4/4885HRH1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.